Stock EWTX EDGEWISE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Edgewise Therapeutics, Inc.

Equities

EWTX

US28036F1057

Real-time Estimate Cboe BZX
Other stock markets
 03:40:49 2024-06-05 pm EDT 		5-day change 1st Jan Change
18.06 USD +3.53% Intraday chart for Edgewise Therapeutics, Inc. +5.06% +65.17%
May. 10 Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating MT
May. 09 Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Edgewise Therapeutics : Corporate Overview, May 2024
PU
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
AQ
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
BU
Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating
MT
Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
BU
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
BU
Edgewise Therapeutics, Inc. Appoints Arlene Morris to Its Board of Directors
CI
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy
AQ
Edgewise Therapeutics Says First Patient Dosed in Phase 2 Hypertrophic Cardiomyopathy Trial
MT
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
BU
Edgewise Therapeutics, Inc Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy
CI
Edgewise Receives European Medicines Agency Orphan Drug Designations for Sevasemten for the Treatment of Becker and Duchenne Muscular Dystrophies
AQ
Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU
MT
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
BU
RBC Raises Price Target on Edgewise Therapeutics to $32 From $28, Keeps Outperform, Speculative Risk
MT
Edgewise Therapeutics : EDG-5506 ARCH 2 YR Topline Results
PU
Sector Update: Health Care Stocks Mixed Premarket Tuesday
MT
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten in Adults with Becker Muscular Dystrophy
AQ
Edgewise Therapeutics : EDG-5506 ARCH 2 YR Topline Results April 2024
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EWTX Stock
  4. News Edgewise Therapeutics, Inc.